Impact Biotech

Impact BiotechImpact Biotech
Impact Biotech

Impact Biotech

Develops and launches Padeliporfin VTP therapy for solid tumor treatment.

DR 191996Active42Tel Aviv, Israel
Rate

About

ImPact Biotech is focused on the development and launch of Padeliporfin VTP (Vascular Targeted Photodynamic) therapy for the treatment of solid tumors. The company is headquartered in Israel, with presence in Luxembourg, France and USA, as well as its own GMP-certified (Good Manufacturing Practice) manufacturing capabilities.
Frequently asked

What does Impact Biotech do?

ImPact Biotech is focused on the development and launch of Padeliporfin VTP (Vascular Targeted Photodynamic) therapy for the treatment of solid tumors. The company is headquartered in Israel, with presence in Luxembourg, France and USA, as well as its own GMP-certified (Good Manufacturing Practice) manufacturing capabilities.

What is Impact Biotech's revenue?

StartupHub estimates Impact Biotech's annual revenue at $7.0M (range $4.0M to $11.2M, 64% confidence), based on comparable companies in the sector.

What is Impact Biotech's valuation?

StartupHub estimates Impact Biotech's effective valuation at $10.3M (range $6.8M to $16.4M, 14% confidence), based on comparable companies in the sector.

How much funding has Impact Biotech raised?

Impact Biotech has raised a total of $3M in funding. The most recent round on record is Grant.

Where is Impact Biotech headquartered?

Impact Biotech is headquartered in Tel Aviv, Israel.

When was Impact Biotech founded?

Impact Biotech was founded in 1996.

What industry does Impact Biotech operate in?

Impact Biotech operates in Life Sciences, Cancer, Therapeutics, Biotech, MedTech, HealthTech.

How many employees does Impact Biotech have?

Impact Biotech has approximately 42 people on record.

HEADCOUNT
42
DOMAIN RATING
19
Comments

No comments yet. Be the first to share your take.